Advanced Cell Diagnostics

Provider of the most advanced
RNA in situ hybridization technology
Banner Image

News

  Secondary Navigation


SIGN UP FOR INFORMATION

Interested in information on new applications, interesting publications, new probe lists, newsletters or case studies? Enter your email address below.

Advanced Cell Diagnostics is Pleased to Announce the launch of their New Website

2013 June 20 | Posted by ACD

HAYWARD, CALIFORNIA–June 18, 2013–Advanced Cell Diagnostics, Inc. (ACD), a biotechnology company developing cell and tissue-based diagnostic tests for personalized medicine, today announced the launch of their newly designed website at www.acdbio.com. The website is designed with a fresh new look and user-friendly navigation and is updated with the latest information about RNAscope® products and services.

The new site offers easier online quote request, improved multi-species target probe search capability, and a blog corner that provides the latest information about RNAscope® products and services. In addition, there is an updated application, documentation and support library, interactive FAQ community, webinars, and online training presentations. For more information about the website, visit the ACD blog at www.acdbio.com/about/blog.

About RNAscope®

RNAscope® technology is the first automated multiplex RNA in situ hybridization platform capable of detecting and quantifying biomarkers with single-molecule sensitivity. Traditionally, RNA biomarkers are analyzed by "grind-and-bind" assays such as RT-PCR in homogenized tissue, which loses information about cellular context and disease microenvironment that is critical for clinical interpretation. RNAscope® provides single-cell gene expression information within the context of intact tissue, enabling both molecular and histopathological analysis on a platform that is compatible with routine clinical specimens and standard clinical laboratory workflow. Unlike IHC antibodies which are available for only a small fraction of the human proteome and not suitable for the emerging class of non-coding RNAs, RNAscope® assays can be developed and validated in two weeks for virtually any gene in any genome. Currently, ACD offers RNAscope-based products and services worldwide to scientists in a broad range of research areas from basic research to companion diagnostics for personalized medicine. Customers include world-renowned academic institutions and all major pharmaceutical/biotech companies.

About Advanced Cell Diagnostics

Advanced Cell Diagnostics, Inc. is a leader in the emerging field of molecular pathology, developing cell and tissue-based diagnostic tests for personalized medicine. The company’s products and services are based on its proprietary RNAscope® technology, the first automated multiplex chromogenic and fluorescent in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity. RNAscope® assays are currently used by hundreds of customers, including all of the global top 10 pharmaceutical companies, world leading academic institutions and many cutting edge biotechnology companies to validate biomarkers for the management of cancer and other diseases. ACD’s industrial partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners’ targeted therapeutics. ACD also pursues internal programs to develop and commercialize proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope® technology at www.acdbio.com.

Press Contact:

Steve Chen, Ph.D.
Chief Operating Officer
(510) 259-9802

schen@acdbio.com

Download Press Release (PDF)

Feedback
Tracker Pixel for Entry